MARKET

ISR

ISR

ISORAY
AMEX

Real-time Quotes | Nasdaq Last Sale

1.300
-0.110
-7.80%
Opening 12:42 03/03 EST
OPEN
1.400
PREV CLOSE
1.410
HIGH
1.411
LOW
1.270
VOLUME
3.88M
TURNOVER
--
52 WEEK HIGH
2.810
52 WEEK LOW
0.3520
MARKET CAP
183.56M
P/E (TTM)
-27.9570
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Isoray to Present at the Oppenheimer 31st Annual Healthcare Conference
RICHLAND, Wash., March 03, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Chief Executive Officer Lori Woods will present at the Oppenheimer 31st Annual Health...
GlobeNewswire · 4h ago
Global Radiation Oncology Market Forecast To 2027 By Trends and Drivers, Restraints, and Opportunities
Japan, Japan, Tue, 02 Mar 2021 02:44:58 / Comserve Inc. / -- Key Players: Accuray Incorporated, Elekta AB, Varian Medical Systems, C.R. Bard, Inc., IBA...
Comserve · 1d ago
Superficial Radiation Therapy System Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Mar 01, 2021 (Market Insight Reports) -- The Global Superficial Radiation Therapy System Market is expected to grow at a CAGR of over 3.7% during the...
Market Insight Reports · 2d ago
Superficial Radiation Therapy System Market is Expected to Witness a CAGR of 3.7% by 2030 | Size in 2021 Estimation, COVID-19 Impact Analysis, Key Insights & Forecast | FMI Report
Feb 26, 2021 (MARKITWIRED via COMTEX) -- Superficial Radiation Therapy Systems Market Analysis 2020-2030 A recent market study published by Future Market...
Markitwired · 5d ago
Top Penny Stocks To Buy Right Now? 4 To Watch After A Pullback
Feb 25, 2021 (Penny Stocks via COMTEX) -- 4 Biotech Penny Stocks To Watch Heading Into March 2021 Like any good investor, the key to picking penny stocks to...
Penny Stocks · 5d ago
Vascular Biogenics, Sunesis Pharmaceuticals leads healthcare gainers; Isoray, Vaccine among major losers
Gainers: Vascular Biogenics (VBLT) +22%, Sunesis Pharmaceuticals (SNSS) +21%, Savara (SVRA) +8%, Pandion Therapeutics (PAND) +5%.Losers: PAVmed PAVM -17%, Isoray (ISR) -16%, Vaccinex (VCNX) -16%, Onconova Therapeutics ONTX -15%, electroCore (ECOR) -14%.
Seekingalpha · 02/23 16:03
Here's Why We're Not At All Concerned With Isoray's (NYSEMKT:ISR) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 02/21 08:51
Brachytherapy Devices Market Size 2021 CAGR Value, Industry Share, Growth by Top Companies, Growth Rate, Trends by Types and Application and Forecast to 2024
The Express Wire · 02/18 08:13
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ISR. Analyze the recent business situations of ISORAY through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ISR stock price target is 2.150 with a high estimate of 3.000 and a low estimate of 1.600.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 3.97M
% Owned: 2.81%
Shares Outstanding: 141.20M
TypeInstitutionsShares
Increased
3
180.54K
New
3
75.96K
Decreased
3
935.88K
Sold Out
6
261.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.62%
Pharmaceuticals & Medical Research
-1.47%
Key Executives
Chairman/Independent Director
Michael McCormick
Chief Executive Officer/Director
Lori Woods
Chief Financial Officer
Jonathan Hunt
Chief Operating Officer/Vice President/Director of Human Resources
Jennifer Streeter
Executive Vice President/Director of Sales/Director of Marketing
Michael Krachon
Chief Accounting Officer/Controller
Mark Austin
Vice President - Business Development
Lisa Lauer
Other
William Cavanagh
Secretary
Krista Cline
Independent Director
Alan Hoffmann
Independent Director
Philip Vitale
  • Dividends
  • Splits
  • Insider Activity
No Data
About ISR
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.

Webull offers kinds of IsoRay, Inc. stock information, including AMEX:ISR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISR stock methods without spending real money on the virtual paper trading platform.